Advertisement
Global Market Insights

Swiss SMI Drops 1.75% on Iran Tensions, Pharma Stocks Fall

June 2, 2026
10:51 AM
3 min read

Key Points

SMI fell 237.26 points or 1.75% to 13,305.40 on June 1 amid U.S.-Iran tensions.

Roche and Novartis dropped over 3% as pharma stocks led the selloff.

Swiss retail sales climbed 1.6% annually in April, beating expectations.

Oil prices climbed toward $92 per barrel on Middle East escalation.

Be the first to rate this article

Switzerland’s SMI benchmark index fell 237.26 points or 1.75% to 13,305.40 on June 1 as U.S.-Iran peace talks stalled and geopolitical tensions escalated. Iran halted negotiations with the U.S. and threatened to close the Strait of Hormuz after Israeli attacks in Lebanon. Oil prices climbed, raising inflation concerns and weighing on equities across Europe.

Advertisement

Pharma Stocks Lead the Decline

Roche fell 3.61% and Novartis dropped 3.33% as investors fled defensive holdings amid geopolitical uncertainty. Sika, Geberit, VAT Group, Helvetia Baloise Holding, and Sandoz Group also declined 2.1% to 2.8%. The broader selloff reflected concerns that sustained high energy prices could force central banks to tighten monetary policy.

Mixed Signals on Geopolitics and Growth

U.S. Central Command conducted self-defense strikes on Iranian radar and command sites over the weekend. Earlier, Iran’s state-affiliated Tasnim outlet said Tehran would halt peace talks and close the Strait of Hormuz. Despite the turmoil, Swiss retail sales climbed 1.6% annually in April, beating expectations of 0.2% growth. This marked the third consecutive monthly expansion.

Energy Stocks and Tech Outperform

Logitech International gained 2.8%, while Kuehne + Nagel and UBS Group rose 1.55% and 1.38%, respectively. Energy stocks benefited from higher oil prices as crude climbed toward $92 per barrel. Across Europe, the Stoxx 600 fell 0.76%, the FTSE 100 dropped 0.68%, and Germany’s DAX closed down 0.4%.

Economic Data Shows Resilience

Swiss gross domestic product grew 0.4% in the first quarter, revised down from 0.5% but still faster than the 0.2% expansion in Q4 2025. On an unadjusted basis, growth accelerated to 0.7%. The data suggests the economy remains stable despite external shocks, though domestic demand remains subdued.

Advertisement

Final Thoughts

The SMI’s 1.75% drop reflects investor anxiety over geopolitical risk and inflation rather than fundamental weakness. With Swiss retail sales beating expectations and GDP growth steady, the selloff appears tactical. Monitor U.S.-Iran developments and oil prices for near-term direction.

FAQs

Why did the SMI fall on June 1?

Iran halted peace talks and threatened to close the Strait of Hormuz after Israeli attacks. Rising oil prices increased inflation concerns, triggering a broad European selloff.

Which sectors were hit hardest?

Pharma stocks led losses with Roche down 3.61% and Novartis down 3.33%. Industrial and consumer stocks also declined as investors sought safety amid geopolitical uncertainty.

Did Swiss economic data support the decline?

No. Retail sales rose 1.6% annually in April, beating forecasts of 0.2%. Q1 GDP grew 0.4%, showing the economy remains resilient despite external shocks.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.

About Author

Author

Huzaifa Zahoor

Co Founder

Huzaifa Zahoor is the engineer who built Meyka. He has spent years writing Python, training AI models, and building data pipelines specifically for financial markets. His technical articles have reached over 30,000 readers on Medium, so he knows how to make complex things easy to follow. If this article touches on how the tools work, he is the person who actually built them.

What brings you to Meyka?

Pick what interests you most and we will get you started.

I'm here to read news

Find more articles like this one

I'm here to research stocks

Ask Meyka Analyst about any stock

I'm here to track my Portfolio

Get daily updates and alerts (coming March 2026)